View Item 

Show simple item record

Association of left ventricular hypertrophy and functional impairment with cardiovascular outcomes and mortality among patients with chronic kidney disease, results from the C‐STRIDE study

dc.contributor.authorWang, Jinwei
dc.contributor.authorLv, Jicheng
dc.contributor.authorHe, Kevin
dc.contributor.authorWang, Fang
dc.contributor.authorGao, Bixia
dc.contributor.authorZhao, Ming-Hui
dc.contributor.authorZhang, Luxia
dc.date.accessioned2022-04-08T18:05:28Z
dc.date.available2023-05-08 14:05:27en
dc.date.available2022-04-08T18:05:28Z
dc.date.issued2022-04
dc.identifier.citationWang, Jinwei; Lv, Jicheng; He, Kevin; Wang, Fang; Gao, Bixia; Zhao, Ming-Hui ; Zhang, Luxia (2022). "Association of left ventricular hypertrophy and functional impairment with cardiovascular outcomes and mortality among patients with chronic kidney disease, results from the C‐STRIDE study." Nephrology 27(4): 327-336.
dc.identifier.issn1320-5358
dc.identifier.issn1440-1797
dc.identifier.urihttps://hdl.handle.net/2027.42/172045
dc.description.abstractAimLeft ventricular hypertrophy and impaired systolic and diastolic function are commonly seen in patients with chronic kidney disease (CKD), but relationships between the disorders and cardiovascular outcomes are not well established among the patients.MethodsTotally, 2020 patients with CKD Stages 1–4 were used in the analysis. Left ventricular hypertrophy was defined by left ventricular mass index >49.2 g/m2.7 in men and > 46.7 g/m2.7 in women. Incident heart failure, non‐heart failure cardiovascular events, and all‐cause mortality were recorded longitudinally. Cox proportional hazards regression model was used to evaluate the association between the echo parameters and the outcomes, with death treated as the competing risk event for the cardiovascular events.ResultsAfter a median follow‐up of 4.5 years, 53 heart failure, 76 non‐heart failure cardiovascular events and 82 deaths occurred. No overall association was found between left ventricular hypertrophy and subsequent heart failure, but the relationship was significant among patients with no diabetes with the multivariable adjusted hazard ratio of 3.66 (95% confidence interval: 1.42–9.46). Ejection fraction<55% was associated with both heart failure and non‐heart failure cardiovascular events with hazard ratios of 3.16 (1.28–7.77) and 2.76 (1.08–7.04), respectively. E/A ratio ≤ 0.75 was associated with non‐heart failure cardiovascular events [hazard ratio = 2.03 (1.09–3.80)], compared with E/A ratio of 0.76–1.49.ConclusionAssociations of reduced left ventricular ejection fraction with both heart failure and non‐heart failure cardiovascular events and of impaired left ventricular diastolic function with non‐heart failure cardiovascular events were validated in a Chinese cohort of CKD.SUMMARY AT A GLANCEThis is a multi‐centre cohort from China on the association of left ventricular hypertrophy and functional impairment with cardiovascular outcomes and mortality in CKD patients. Ejection fraction <55% was associated with both heart failure and non‐heart failure cardiovascular events.
dc.publisherJohn Wiley & Sons Australia, Ltd
dc.subject.otherall‐cause mortality
dc.subject.othercardiovascular disease
dc.subject.otherchronic kidney disease
dc.subject.othercohort
dc.subject.otherechocardiography
dc.titleAssociation of left ventricular hypertrophy and functional impairment with cardiovascular outcomes and mortality among patients with chronic kidney disease, results from the C‐STRIDE study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172045/1/nep14009.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172045/2/nep14009_am.pdf
dc.identifier.doi10.1111/nep.14009
dc.identifier.sourceNephrology
dc.identifier.citedreferenceAhmad FS, Cai X, Kunkel K, et al. Racial/ethnic differences in left ventricular structure and function in chronic kidney disease: the chronic renal insufficiency cohort. Am J Hypertens. 2017; 30: 822 ‐ 829.
dc.identifier.citedreferenceDi Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and cardiovascular complications. Heart Fail Rev. 2015; 20: 259 ‐ 272.
dc.identifier.citedreferenceZoccali C, Benedetto FA, Tripepi G, et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol. 2006; 17: 1460 ‐ 1465.
dc.identifier.citedreferenceBansal N, Katz R, Himmelfarb J, et al. Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson heart study. Nephrol Dial Transplant. 2016; 31: 2057 ‐ 2064.
dc.identifier.citedreferenceZoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow‐up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65: 1492 ‐ 1498.
dc.identifier.citedreferencePeterson GE, de Backer T, Contreras G, et al. Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease. Hypertension. 2013; 62: 518 ‐ 525.
dc.identifier.citedreferenceDubin RF, Deo R, Bansal N, et al. Associations of conventional echocardiographic measures with incident heart failure and mortality: the chronic renal insufficiency cohort. Clin J Am Soc Nephrol. 2017; 12: 60 ‐ 68.
dc.identifier.citedreferenceChen SC, Chang JM, Liu WC, et al. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant. 2012; 27: 1064 ‐ 1070.
dc.identifier.citedreferenceGao B, Zhang L, Wang H, Zhao M. Chinese cohort study of chronic kidney disease: design and methods. Chin Med J. 2014; 127: 2180 ‐ 2185.
dc.identifier.citedreferenceSchiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two‐dimensional echocardiography. American Society of Echocardiography Committee on standards, subcommittee on quantitation of two‐dimensional echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358 ‐ 367.
dc.identifier.citedreferenceDevereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450 ‐ 458.
dc.identifier.citedreferencede Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 1251 ‐ 1260.
dc.identifier.citedreferenceBella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle‐aged and elderly adults: the strong heart study. Circulation. 2002; 105: 1928 ‐ 1933.
dc.identifier.citedreferenceLevey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604 ‐ 612.
dc.identifier.citedreferenceAustin PC, Fine JP. Practical recommendations for reporting Fine‐Gray model analyses for competing risk data. Stat Med. 2017; 36: 4391 ‐ 4400.
dc.identifier.citedreferenceFine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Publ Am Stat Assoc. 1999; 94: 496 ‐ 509.
dc.identifier.citedreferenceNitta K, Iimuro S, Imai E, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD‐JAC study. Clin Exp Nephrol. 2019; 23: 85 ‐ 98.
dc.identifier.citedreferenceKang E, Lee J, Kim HJ, et al. The association between socioeconomic disparities and left ventricular hypertrophy in chronic kidney disease: results from the KoreaN cohort study for outcomes in patients with chronic kidney disease (KNOW‐CKD). BMC Nephrol. 2018; 19: 203.
dc.identifier.citedreferenceKy B, Shults J, Keane MG, et al. FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail. 2013; 6: 817 ‐ 824.
dc.identifier.citedreferenceScialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor‐23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014; 25: 349 ‐ 360.
dc.identifier.citedreferenceShlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005; 293: 1737 ‐ 1745.
dc.identifier.citedreferenceJain A, Scott C, Chen HH. The renal‐cardiac connection in subjects with preserved ejection fraction: a population based study. ESC Heart Fail. 2017; 4: 266 ‐ 273.
dc.identifier.citedreferenceBadve SV, Palmer SC, Strippoli GFM, et al. The validity of left ventricular mass as a surrogate end point for all‐cause and cardiovascular mortality outcomes in people with CKD: a systematic review and meta‐analysis. Am J Kidney Dis. 2016; 68: 554 ‐ 563.
dc.identifier.citedreferenceYusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high‐income, middle‐income, and low‐income countries (PURE): a prospective cohort study. Lancet. 2020; 395: 795 ‐ 808.
dc.identifier.citedreferenceHensen LCR, Goossens K, Delgado V, et al. Prevalence of left ventricular systolic dysfunction in pre‐dialysis and dialysis patients with preserved left ventricular ejection fraction. Eur J Heart Fail. 2018; 20: 560 ‐ 568.
dc.identifier.citedreferenceSulemane S, Panoulas VF, Bratsas A, Grapsa J, Brown EA, Nihoyannopoulos P. Subclinical markers of cardiovascular disease predict adverse outcomes in chronic kidney disease patients with normal left ventricular ejection fraction. Int J Cardiovasc Imaging. 2017; 33: 687 ‐ 698.
dc.identifier.citedreferenceKim JS, Yang JW, Yoo JS, Choi SO, Han BG. Association between E/e ratio and fluid overload in patients with predialysis chronic kidney disease. PLoS One. 2017; 12: e0184764.
dc.identifier.citedreferenceGo AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296 ‐ 1305.
dc.identifier.citedreferenceMatsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta‐analysis of individual participant data. Lancet Diabetes Endocrinol. 2015; 3: 514 ‐ 525.
dc.identifier.citedreferencePark M, Hsu CY, Go AS, et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all‐cause death: the CRIC study. Clin J Am Soc Nephrol. 2017; 12: 761 ‐ 771.
dc.identifier.citedreferenceDi Lullo L, Floccari F, Santoboni A, et al. Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol. 2013; 26: 739 ‐ 744.
dc.identifier.citedreferenceLezaic V, Tirmenstajn‐Jankovic B, Bukvic D, et al. Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol. 2009; 71: 21 ‐ 29.
dc.identifier.citedreferenceParikh SV, de Lemos JA. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci. 2006; 332: 186 ‐ 197.
dc.identifier.citedreferenceOlgaard K, Lewin E, Silver J. Calcimimetics, vitamin D and ADVANCE in the management of CKD‐MBD. Nephrol Dial Transplant. 2011; 26: 1117 ‐ 1119.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
nep14009.pdf
Size:
1.215MB
Format:
PDF
View/Open
Name:
nep14009_am.pdf
Size:
592.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.